In the spirit of progress and advancement, the 2020 ESMO World Congress on GI Cancer will be delivered as a virtual experience. With more than 90 scientific sessions dedicated to improving the lives of patients with GI cancer, this meeting offers important knowledge for everyone involved.

Register Today
worldgicancer.com
+1.678.242.0906

THE CONGRESS CHAIRS

DEDICATED TO DELIVERING UNMATCHED EDUCATION ON THE LATEST ADVANCEMENTS IN GI ONC可靠的

CHAIR
Mario Dicato
Luxembourg, Luxembourg

CHAIR
Eric Van Cutsem
Leuven, Belgium

VICE CHAIR
Josep Tabernero
Barcelona, Spain

3,500+
Delegates

120+
Countries Represented

80+
GI Oncology Experts

450+
Scientific Abstracts
The Congress will be completely accessible from the comfort of your home via any device—all you need is an internet connection.

Your Virtual Registration includes:

- 4 days of live access to the very latest clinical highlights—including 50+ oral abstract presentations, featuring important data and practice-changing insight
- Access to all sessions traditionally delivered during a face-to-face gathering—plus additional sessions released weekly as an on-demand component of the educational program
- 12-month on-demand access to all educational sessions recorded during the live program as well as to those added once the live program concludes—watch at your convenience
- Engaging exchange through real-time Q&A and discussion with our globally recognized faculty experts
- Beyond the educational program, connect with your global community by participating in independent satellite symposia and networking opportunities, and browsing the exhibit hall.

Visit worldgicancer.com/virtualFAQ to learn more
The Scientific Committee

Composed of some of the world’s leading experts, the Scientific Committee has worked to develop a robust and unmatched scientific program for a critical and comprehensive update in GI cancer.

Ghassan K. Abou-Alfa
Memorial Sloan Kettering Cancer Center
New York, United States

Scott Kopetz
MD Anderson Cancer Center
The University of Texas
Houston, United States

Renê Adam
Université Paris Sud Hôpital
Paul Brousse
Villejuif, France

Teresa Macarulla
Vall d’Hebron University Hospital
Barcelona, Spain

Thierry André
Hospital Saint Antoine
Paris, France

Vincenzo Mazzaferrro
Istituto Nazionale per lo Studio e la Cura dei Tumori
Milan, Italy

Teresa Amaral
Eberhard Karls University
Tuebingen, Germany

Markus Möhler
University Medicine of the Johannes Gutenberg-University Mainz
Mainz, Germany

Irir Ben-Aharon
Rambam Health Care Campus
Haifa, Israel

Magnus Nilsson
Karolinska Institutet
Karolinska University Hospital
Stockholm, Sweden

Jacques J. Bergman
Academic Medical Center
Amsterdam, Netherlands

Eileen M. O’Reilly
Memorial Sloan Kettering Cancer Center
New York, United States

Jaume Capdevila
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Michael Overman
MD Anderson Cancer Center
The University of Texas
Houston, United States

Andrea Cercek
Memorial Sloan Kettering Cancer Center
New York, United States

Christopher H. Crane
Memorial Sloan Kettering Cancer Center
New York, United States

Christophe Derouesne
University Hospital
Gasthuisberg
Leuven, Belgium

Teresa Macarulla
Vall d’Hebron University Hospital
Barcelona, Spain

Christophe Derouesne
University Hospital
Gasthuisberg
Leuven, Belgium

Solange Peters
Lausanne University Hospital
Lausanne, Switzerland

Andrés Cervantes
Blonbiomedical Research Institute
INCLIVA
University of Valencia
Valencia, Spain

Erika Ruíz-García
Instituto Nacional de Cancerología
Mexico City, Mexico

Michel P. Ducreux
Gustave Roussy
Paris, France

Thomas Tejpar
University Hospital Gasthuisberg
Leuven, Belgium

Maria Reig
Barcelona Clinic Liver Cancer
Hospital Clinic de Barcelona
Barcelona, Spain

Marianne Pavel
Friedrich-Alexander University
Erlangen, Germany

Barbara Paoletti
University of Florence
Florence, Italy

José Figueras
University Hospital Complex
Barcelona, Spain

Laura Casazza
University of Pisa
Pisa, Italy

Stefano Vellutini
University of Rome Tor Vergata
Rome, Italy

*Confirmed as of May 12.
For the most up-to-date faculty list, please visit worldgicancer.com

Faculty
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td>Welcome and Introduction</td>
</tr>
<tr>
<td>13:15</td>
<td>Concurrent Symposia</td>
</tr>
<tr>
<td>14:15</td>
<td>Presentation of Selected Abstracts on Biliary Tract and Pancreatic Cancers</td>
</tr>
<tr>
<td>16:24</td>
<td>Live Q&amp;A With Key Opinion Leaders</td>
</tr>
<tr>
<td>16:44</td>
<td>Break</td>
</tr>
<tr>
<td>17:00</td>
<td>Concurrent Symposia</td>
</tr>
<tr>
<td>18:00</td>
<td><strong>KEYNOTE:</strong> New Agents on the Horizon in Metastatic Disease (Biliary Duct and Pancreatic Cancer)</td>
</tr>
<tr>
<td>18:20</td>
<td>Presentation of Selected Abstracts on Hepatocellular Cancer</td>
</tr>
<tr>
<td>19:58</td>
<td><strong>KEYNOTE:</strong> How to Integrate New Agents in HCC</td>
</tr>
<tr>
<td>20:18</td>
<td>Live Q&amp;A With Key Opinion Leaders</td>
</tr>
<tr>
<td>20:38</td>
<td>Adjourn</td>
</tr>
<tr>
<td>13:00</td>
<td>2 July 2020</td>
</tr>
<tr>
<td>13:15</td>
<td>Concurrent Symposia</td>
</tr>
<tr>
<td>14:15</td>
<td>Presentation of Selected Abstracts on Gastric Cancer</td>
</tr>
<tr>
<td>15:58</td>
<td>Live Q&amp;A With Key Opinion Leaders</td>
</tr>
<tr>
<td>16:18</td>
<td>Break</td>
</tr>
<tr>
<td>16:40</td>
<td><strong>KEYNOTE:</strong> Checkpoint inhibition in Esophageal and Metastatic Gastric Cancer</td>
</tr>
<tr>
<td>17:00</td>
<td>Concurrent Symposium</td>
</tr>
<tr>
<td>18:00</td>
<td><strong>KEYNOTE:</strong> New Agents on the Horizon in Esophageal and Gastric Cancer</td>
</tr>
<tr>
<td>18:20</td>
<td>Presentation of Selected Abstracts</td>
</tr>
<tr>
<td>19:50</td>
<td>Presentation of Selected Abstracts</td>
</tr>
<tr>
<td>19:15</td>
<td>DISCUSSANT/LECTURE: Early Detection of Cancer in the Normal Population</td>
</tr>
<tr>
<td>19:24</td>
<td>DISCUSSANT/LECTURE: Artificial Intelligence and Machine Learning in Cancer Imaging</td>
</tr>
<tr>
<td>19:39</td>
<td>Presentation of Selected Abstracts</td>
</tr>
<tr>
<td>19:46</td>
<td>DISCUSSANT/LECTURE: Radiomics in Imaging</td>
</tr>
<tr>
<td>20:01</td>
<td>Live Q&amp;A With Key Opinion Leaders</td>
</tr>
<tr>
<td>20:21</td>
<td>Adjourn</td>
</tr>
</tbody>
</table>
Saturday
4 July 2020

12:00
Welcome and Introduction; Highlights of Day 3

12:15
Concurrent Symposia

SESSION VIII
KEYNOTE PRESENTATIONS I
13:15
KEYNOTE: Women in Oncology

13:35
KEYNOTE: COVID-19 and Cancer

SESSION IX
RECTAL CANCER
13:55
Presentation of Selected Abstracts

14:24
KEYNOTE: Total Neoadjuvant Treatment in Rectal Cancer: Reality or Myth?

14:44
Live Q&A With Key Opinion Leaders

SESSION X
KEYNOTE PRESENTATIONS II
15:04
KEYNOTE: Harmful Drug Interactions in GI Oncology

15:24
KEYNOTE: Relevant Pathways in Immuno-Oncology

15:44
Break

16:10
Concurrent Symposium

SESSION XI
POSTER DISCUSSIONS
17:10
HCC/Biliary Tract Cancer

17:20
Pancreatic Cancer

17:30
Colon Cancer

17:40
Other

17:50
Live Q&A With Key Opinion Leaders

18:10
Adjourn

Friday
3 July 2020

12:00
Welcome and Introduction; Highlights of Day 2

12:15
Concurrent Symposia

SESSION VI
COLORECTAL CANCER I
13:15
Presentation of Selected Abstracts on Colorectal Cancer

15:40
Live Q&A With Key Opinion Leaders

16:00
Break

16:10
Concurrent Symposia

SESSION VII
COLORECTAL CANCER II
17:30
Presentation of Selected Abstracts on Colorectal Cancer

20:10
Live Q&A With Key Opinion Leaders

20:30
Adjourn
EXPANDED ON-DEMAND PROGRAMME

NEW

In addition to our live scientific programme, a 13-session, 15.6-hour expanded on-demand programme will be included in your registration. This programme will release therapy focused sessions over a period of several weeks following the virtual broadcast.

CANCER OF THE PANCREAS AND BILIARY TRACT
Hereditary Pancreatic Cancer: Genetics and Surveillance
Targeting the Microenvironment and the Immune System
How to Integrate and Interpret Best Imaging in Locally Advanced PDAC and What to Use for Response Evaluation: EUS, PET/CT, MRI
Debate: Neoadjuvant Treatment for Resectable Pancreatic Cancer
Treatment Modalities for Locally Advanced Pancreatic Cancer (Including SBRT, Ablation)
The Actual Algorithm in Advanced PDAC: A Strategic Approach (Covering Later Lines, PARP)
Druggable Molecular Alterations in Bile Duct Cancer
Locally Advanced Bile Duct Cancer

PROGRESS IN GI CANCER
How Can Consortia Contribute to the Progress in GI Oncology?
Contribution of the ARCAD Group
Contribution of the ACCENT Group
Teaching and Interpreting Statistics for Clinicians
Reporting on Endpoints: The Example in CRC
Debate: Neoadjuvant Treatment for Resectable Pancreatic Cancer
Treatment Modalities for Locally Advanced Pancreatic Cancer (Including SBRT, Ablation)
The Actual Algorithm in Advanced PDAC: A Strategic Approach (Covering Later Lines, PARP)
Druggable Molecular Alterations in Bile Duct Cancer
Locally Advanced Bile Duct Cancer

IMPACT OF PATIENT FACTORS IN DISEASE BIOLOGY IN GI CANCER: GENDER AND AGE
The Explosion of CRC (or GI Cancer) in Young Adults: Why?
Why Does Gender Matter for Treatment?
RELEVANT PATHWAYS IN GI CANCER: HOW RELEVANT AND HOW TO APPROACH THEM
The HER2 Pathway in GI Cancer
FGFR and Other Fusions in GI Cancer
Should DPD Deficiency Be Tested Before Starting 5FU?
How to Interpret an NGS Sequencing Report
Debate: Tumor or Liquid Biopsies in the Future?

KEYNOTE PRESENTATIONS
KEYNOTE: Integrating Health Economic Evaluation into Daily Practice in the COVID-19 Era
KEYNOTE: New Promising PET Tracers

HEPATOCELLULAR CANCER
Can We Maximize the Benefit of IO in HCC?
Locoregional Treatment in HCC
Liver Transplantation in the COVID-19 Era

MULTIMODALITY THERAPY FOR RECTAL CANCER
Neoadjuvant Treatment: How and for Whom?
Organ Preserving Strategy
Local Excision (TEM/TAM) vs. Radical Resection: When and in Whom?
Case Presentations

KEYNOTE PRESENTATIONS
KEYNOTE: Integrating Health Economic Evaluation into Daily Practice in the COVID-19 Era
KEYNOTE: New Promising PET Tracers

IMMUNE MECHANISMS AND IMMUNE THERAPY IN GI CANCER
Biomarkers for Checkpoint Inhibitors in GI Cancer
How Can We Increase the Immunogenicity in MSS CRC?
The Link Between the Immune Microenvironment and Outcomes in Colorectal Cancer
New Immunotherapy Combinations (anti VEGF + CPI; CART; TKIs + CPI) in GI Cancers

MOLECULAR BIOLOGY IN COLORECTAL CANCER
Liver Transplantation in GI Cancer: A Reality or an Illusion? The Case in NET, Cholangiocarcinoma, and CRC
Genetic Risk Factors for GI Cancers/Hereditary Syndromes

COLORECTAL CANCER
Treatment Algorithm in mCRC: How to Select First-Line Therapy
Treatment Algorithm in mCRC: Later Lines
Adjuvant Treatment for Stage II–III Colon Cancer

NEW BREAKTHROUGH IN RARE CANCERS
What is New in GIST in the Last 12 Months?
What is New in Pancreatic NETs in the Last 12 Months?
What is New in Non-Pancreatic NETs in the Last 12 Months?
What is New on Debulking and HIPEC in Peritoneal Carcinomatosis in the Last 12 Months?
An innovative virtual Exhibition offers Congress participants a unique and interactive opportunity to engage with industry representatives to discover the latest approaches to treatment and groundbreaking medical technologies focused on treating patients with gastrointestinal cancers.

The ESMO World Congress on GI Cancer is part of the Oncology Learning Network.

Visit Oncology Learning Network, the digital home of ESMO World Congress on GI Cancer, for exclusive access to session abstracts, multimedia interviews with key opinion leaders, and news coverage of this year’s event and more at www.oncnet.com
## Continuing Education

### ESMO-MORA

The Congress programme will be submitted for ESMO-MORA category 1 points accreditation. Re-certification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and possesses the necessary skills and standards for the practice of medical oncology.

### Who Should Attend

This Congress is specifically designed for practicing clinicians, gastroenterologists, hepatologists, pathologists, surgeons, medical oncologists, radiation oncologists, and clinical researchers who wish to review and update their knowledge and management of cancers of the gastrointestinal tract.

### Learning Objectives

After attending this Congress, participants should be able to:

- Identify current controversies in the management of patients with gastric or esophageal cancers
- Discuss contemporary treatment options for patients with gastric or esophageal cancers
- Comment on available treatment options for rare gastrointestinal and neuroendocrine tumors
- Describe the epidemiology and pathogenesis of hepatocellular carcinoma
- Discuss management of patients with liver cancer
- Identify adjuvant and neoadjuvant treatment options for patients with locally advanced and metastatic cancer of the pancreas
- Select the most appropriate detection, screening, and chemoprevention methods for colorectal cancer
- Describe the use of molecular markers for screening and prognosis of colorectal cancer and gastric cancer
- Select the most appropriate adjuvant and neoadjuvant treatments for colorectal cancer patients
- Comment on new agents in the treatment of colorectal cancer and the latest clinical trials results
- Identify treatment strategies for rectal cancer
- Distinguish appropriate surgical techniques for the treatment of gastrointestinal cancer
- Identify adjuvant and neoadjuvant treatment options for patients with locally advanced and metastatic cancer of the pancreas
- Select the most appropriate detection, screening, and chemoprevention methods for colorectal cancer
- Describe the use of molecular markers for screening and prognosis of colorectal cancer and gastric cancer
- Select the most appropriate adjuvant and neoadjuvant treatments for colorectal cancer patients
- Comment on new agents in the treatment of colorectal cancer and the latest clinical trials results
- Identify treatment strategies for rectal cancer
- Distinguish appropriate surgical techniques for the treatment of gastrointestinal cancer

## Registration

### Groups

Groups of 10 or more should register by contacting the registration team directly at registration@imedex.com to complete the Group Registration Form.

<table>
<thead>
<tr>
<th>ESMO Member</th>
<th>Registration Rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician</td>
<td>€ 399</td>
</tr>
<tr>
<td>PhD, PharmD</td>
<td>€ 239</td>
</tr>
<tr>
<td>Nurse, Student, Trainee, Fellow, Resident, Nurse Practitioner, Physician Assistant</td>
<td>€ 59</td>
</tr>
<tr>
<td>Pharmaceutical Industry Representative</td>
<td>€ 649</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Non-ESMO Member</th>
<th>Registration Rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician</td>
<td>€ 499</td>
</tr>
<tr>
<td>PhD, PharmD</td>
<td>€ 299</td>
</tr>
<tr>
<td>Nurse, Student, Trainee, Fellow, Resident, Nurse Practitioner, Physician Assistant</td>
<td>€ 79</td>
</tr>
<tr>
<td>Pharmaceutical Industry Representative</td>
<td>€ 649</td>
</tr>
</tbody>
</table>

Register online at [worldgicancer.com](http://worldgicancer.com)

Call +1 678.242.0906

Email: registration@imedex.com